UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2010

MICROMET, INC.
(Exact Name of Registrant as Specified in its Charter)

 
Delaware
0-50440
52-2243564
(State or Other Jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification No.)

 
 
6707 Democracy Boulevard, Suite 505, Bethesda, MD
20817
(Address of Principal Executive Offices)
(Zip Code)

 
Registrant’s telephone number, including area code: (240) 752-1420

 
  
(Former Name or Former Address, if Changed Since Last Report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 
Section 7 – Regulation FD
 
Item 7.01. Regulation FD Disclosure
 
The information contained in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Micromet, Inc. (the “Company”) is furnishing this information to disclose that it has recalled a batch of diluent, a liquid used to dilute MT110 drug product for administration to patients. The recall was necessary because of potential damage to the primary packaging material of the diluent. Due to the batch recall, the Company currently does not have diluent available for the ongoing phase 1 clinical trial with MT110 and is therefore not treating patients in the trial. Production of a new batch of diluent is ongoing at a third party manufacturer and the Company expects to resume treatment of patients in the phase 1 trial in the first quarter of 2011. The Company expects to provide an update on data from the clinical trial in the second half of 2011.




 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
MICROMET, INC.
  
       
       
       
       
Date: October 22, 2010
By:
/s/ Matthias Alder
  
 
Name:
Matthias Alder
  
 
Title:
Senior Vice President & General Counsel